For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

The National Multiple Sclerosis Society (USA) has awarded a grant of 1 million dollars to Dr. Isabel Pérez-Otaño, who leads the Plasticity and Remodeling of Neural Circuits laboratory at the Institute ...

These findings showed that patients receiving continuous Zeposia treatment for up to five years experienced ... and cognitive decline,” said Jeffrey Cohen, MD, Mellen Center for Multiple Sclerosis, ...

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...